1
|
Wang J, Bediaga N, Mallone R, Larger E, Harrison LC, Wentworth JM. Validation in the general population of a C-peptide estimate equation to measure beta cell function in recent-onset type 1 diabetes. Acta Diabetol 2021; 58:115-117. [PMID: 32940799 DOI: 10.1007/s00592-020-01604-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Accepted: 09/03/2020] [Indexed: 10/23/2022]
Affiliation(s)
- Joanna Wang
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, 3050, Australia
| | - Naiara Bediaga
- Walter and Eliza Hall Institute Department of Population Health and Immunity, 1G Royal Parade, Parkville, 3052, Australia
- Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia
| | - Roberto Mallone
- Université de Paris, Institut Cochin, CNRS, INSERM, 75014, Paris, France
- Service de Diabétologie Et Immunologie Clinique, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université de Paris, Cochin Hospital, 75014, Paris, France
| | - Etienne Larger
- Université de Paris, Institut Cochin, CNRS, INSERM, 75014, Paris, France
- Service de Diabétologie Et Immunologie Clinique, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université de Paris, Cochin Hospital, 75014, Paris, France
| | - Leonard C Harrison
- Walter and Eliza Hall Institute Department of Population Health and Immunity, 1G Royal Parade, Parkville, 3052, Australia
- Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia
| | - John M Wentworth
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, 3050, Australia.
- Walter and Eliza Hall Institute Department of Population Health and Immunity, 1G Royal Parade, Parkville, 3052, Australia.
- Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.
| |
Collapse
|
2
|
Wang J, Bediaga N, Mallone R, Larger E, Harrison LC, Wentworth JM. Correction to: Validation in the general population of a C-peptide estimate equation to measure beta cell function in recent-onset type 1 diabetes. Acta Diabetol 2021; 58:119. [PMID: 33067722 DOI: 10.1007/s00592-020-01616-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Joanna Wang
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, 3050, Australia
| | - Naiara Bediaga
- Walter and Eliza Hall Institute Department of Population Health and Immunity, 1G Royal Parade, Parkville, 3052, Australia
- Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia
| | - Roberto Mallone
- Université de Paris, Institut Cochin, CNRS, INSERM, 75014, Paris, France
- Service de Diabétologie Et Immunologie Clinique, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université de Paris, Cochin Hospital, 75014, Paris, France
| | - Etienne Larger
- Université de Paris, Institut Cochin, CNRS, INSERM, 75014, Paris, France
- Service de Diabétologie Et Immunologie Clinique, Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université de Paris, Cochin Hospital, 75014, Paris, France
| | - Leonard C Harrison
- Walter and Eliza Hall Institute Department of Population Health and Immunity, 1G Royal Parade, Parkville, 3052, Australia
- Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia
| | - John M Wentworth
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, 3050, Australia.
- Walter and Eliza Hall Institute Department of Population Health and Immunity, 1G Royal Parade, Parkville, 3052, Australia.
- Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.
| |
Collapse
|
3
|
Harding AL, Bediaga N, Galligan A, Colman PG, Fourlanos S, Wentworth JM. Factors that predict glycaemic response to sodium-glucose linked transporter (SGLT) inhibitors. Intern Med J 2020; 51:515-519. [PMID: 32092242 DOI: 10.1111/imj.14805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 02/11/2020] [Accepted: 02/17/2020] [Indexed: 11/26/2022]
Abstract
AIM To determine the clinical and biochemical variables associated with change in HbA1c in patients with type 2 diabetes who start sodium-glucose linked transporter (SGLT) inhibitor therapy. METHODS We performed a prospective cohort study (ACTRN12616000833460) of 48 adults (30 male, 18 female) with type 2 diabetes who attended a tertiary hospital diabetes clinic. Fasting serum and urine samples, collected during clinic visits prior to and at 1, 12 and 24 weeks after commencing SGLT inhibitor treatment, were analysed for HbA1c, electrolytes, urea, creatinine and glucose. RESULTS After 12 weeks, SGLT inhibitor therapy was associated with respective median (97% CI) decreases in weight, blood pressure, HbA1c and urine albumin/creatinine ratio of 3.0 (1.7-3.4) kg, 8 (2-16)/4 (3-9) mmHg, 6 (3-14) mmol/mol and 0.69 (0.18-1.8) mg/mmol. These effects persisted to 24 weeks. Urinary frequency and genitourinary infection were common adverse effects. Baseline HbA1c and eGFR independently predicted ΔHbA1c at 12 weeks whereas only baseline HbA1c independently predicted ΔHbA1c at 24 weeks. Urinary fractional glucose excretion and change in fasting glucose 1 week after starting SGLT inhibitor did not contribute to prediction of glycaemic response. CONCLUSIONS SGLT inhibitor therapy in a hospital clinic setting was associated with clinical improvements comparable to those observed in clinical trials but with higher incidence of genitourinary side-effects. Baseline HbA1c and eGFR, but not urine fractional glucose excretion, predicted glycaemic response.
Collapse
Affiliation(s)
- Amy L Harding
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Naiara Bediaga
- Division of Population Health and Immunity, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia
| | - Anna Galligan
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Peter G Colman
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Spiros Fourlanos
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.,Department of Medicine, Royal Melbourne Hospital University of Melbourne, Melbourne, Victoria, Australia
| | - John M Wentworth
- Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.,Division of Population Health and Immunity, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.,Department of Medicine, Royal Melbourne Hospital University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
4
|
Bediaga N, Davies MPA, Raji OY, Alfirevic A, Liloglou T, Field JK. Abstract 4133: MicroRNAs for early detection of lung cancer. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-4133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Early detection of lung cancer by screening of high risk populations (identified by epidemiological and life-style factors) has the potential to save many lives. However, effective screening is reliant on minimally invasive techniques, such as CT screening, bronchioalveolar lavage (BAL) and blood tests, and the identification of suitable biomarkers. CT screening is effective in reducing mortality, but generates a large proportion of indeterminate nodules that must be further characterised. MicroRNAs (miRNA) have great potential as biomarkers due to their tissue-specific and cancer-specific expression patterns. We have identified tumour-specific miRNAs for non-small cell lung cancer (NSCLC), using a combination of screening on TaqMan microRNA TLDA cards and validation with qRTPCR assays, with the aim of utilising these as biomarkers in the early detection setting. Methods: Our sample group consisted of 31 frozen samples from 20 Liverpool Lung Project (LLP) NSCLC patients, including 10 adenocarcinomas (Ad), 10 squamous cell carcinomas (SCC) & matched normal tissue. Two further validation sets consisted of equal numbers of Ad and SCC tumour/normal pairs (124 in total). MiRNA was prepared from tumour and normal specimens using Qiagen MicroRNeasy kits. Reverse transcription and pre-amplification was performed using Applied Biosystems MegaPlex Pools and miRNAs were quantified on a 7900HT Real-Time PCR System with TaqMan Array Human MiRNA Card Set v3.0 (covering 754 human miRNAs). Ct values were exported using SDS v2.3 data and RQ Manager software and further analysed in Bioconductor. Validation qRTPCR was performed with individual miRNA assays, following reverse transcription with MegaPlex pools. Results: When Benjamin-Hoechst-adjusted-p value <0.05 was used as a cut-off, of the 754 miRNA targets, 68 miRNAs were upregulated and 8 were downregulated with >4.0 fold-change in the cancer group. A subset of 22 miRNAs including miR-34a, miR-96, let-7g and miR-183 was identified with the greatest expression in tumours. Differential expression of all 22 miRNAs was confirmed in an independent set of 24 tumour/normal pairs. Using these 22 validated miRNAs we performed discriminative modelling and identified a model based on just 8 markers that gave a specificity of 100% and a sensitivity of 98%. This panel was validated, with 97% specificity and 91% sensitivity, in a 2nd independent sample set containing 48 tumours and paired normal samples. Conclusion: A number of miRNAs was identified that showed good discriminatory power individually, but greatest sensitivity and specificity when combined as an 8 member panel. The lung cancer specific miRNAs we have identified provide a potential source of early detection biomarkers. Their applicability to minimally-invasive samples is being evaluated in a range of samples including plasma and bronchial lavage.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4133. doi:1538-7445.AM2012-4133
Collapse
|